Quantum BioPharma is trading at $2.50, up 10.13%, with no clearly price-driving company announcement for October 23 identified in available coverage. - Latest reported company news was an October 6 agreement to start Phase 2 trial activities with Thermo Fisher. - A Buy rating and $8.00 target were reported, but coverage began earlier and does not establish a fresh catalyst. - Major indexes were slightly lower in the supplied pre-market context, offering no broader-market explanation for the gain.